Out-licensing and domestic deals drive big numbers in August
Minhua Chu · 09/24/2021
There were 18 new drug licensing deals in August 2021, the most in eight months. The 12 deals that were publicly disclosed reached a total value of $3.44 billion, representing another record.
READ MORE

Latest Articles

Psoriasis’ drug Taltz seeking the new market approval for axSpA
Sarina Yang · 2 days ago
axSpA is a chronic autoimmune diseases Ixekizumab is an inhibitor targeting interleukin 17A (IL-17A) that selectively binds IL-17A and inhibits its interaction with the IL-17 receptor.
News
Zai Lab aims 15 products in over 35 indications by 2025
Elise Mak · 2 days ago
Zai Lab CEO Samantha Du said the company expects "to have more than 15 marketed products in more than 35 indications by 2025."
News
Out-licensing and domestic deals drive big numbers in August
Minhua Chu · 2 days ago
There were 18 new drug licensing deals in August 2021, the most in eight months. The 12 deals that were publicly disclosed reached a total value of $3.44 billion, representing another record.
China Deals Tracker
Everest partners with AbCellera to gain antibodies for up to 10 targets
Sarina Yang · 2 days ago
​Everest Medicines and AbCellera entered a multi-year collaboration to discover therapeutic antibodies for up to 10 targets selected by Everest. This is the third deal Everest disclosed in two weeks.
News
Clover's COVID-19 vaccine is 79% protective against Delta in global phase II/III trial
Elise Mak · 3 days ago
SCB-2019 demonstrated 79% overall efficacy against COVID-19 of any severity caused by the globally dominant Delta variant, 92% against the Gamma variant and 59% against the Mu variant.
News
Innovent's NDA for PD-1 drug as first-line treatment for ESCC accepted in China
Elise Mak · 3 days ago
China's NMPA has accepted the supplemental NDA for Innovent's PD-1 drug sintilimab in combination with chemotherapy as the first-line treatment of esophageal squamous cell carcinoma.
News
Ascentage's MDM2-p53 Inhibitor wins fast track from FDA in r/r melanoma
Elise Mak · 3 days ago
Ascentage's MDM2-p53 inhibitor alrizomadlin (APG-115) has been granted a fast track designation by the FDA for treating unresectable or metastatic melanoma, relapsed/refractory to prior immuno-oncologic agent treatments.
News
China sees a future for domestically produced insulin
Minhua Chu · 3 days ago
China's latest insulin volume-based procurement is poised to change the market value of insulin, paving way for domestic insulin products to enter large hospitals.
Regulatory
CStone and EQRx report phase III data of sugemalimab at ESMO
Elise Mak · 4 days ago
Sugemalimab, as a consolidation therapy, demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus placebo.
News
Innovent posts positive phase II data of pemigatinib at ESMO
Elise Mak · 4 days ago
Among 30 efficacy evaluable subjects, 15 of them had confirmed response assessed by independent radiological review committee, with an objective response rate of 50% (95% CI: 31.3%, 68.7%).
News
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement